Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Noninvasive Assessment of Pulmonary Fluid Levels by Remote Dielectric Sensing Technology to Improve Cardiac InsUfficieney During Ischemia-Reperfusion and Clinical Outcomes in MyocArdiaL Infarction

NCT06671067 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2024-11-01
Last updated
2024-11-04

Condition(s) studied

Acute Myocardial InfarctionAcute Decompensated Heart Failure (ADHF)

Investigational drug(s) / intervention(s)

Remote dielectric sensing system

Remote dielectric sensing system: The remote dielectric sensing (ReDS) system is a non-invasive medical device that emits a low-power electromagnetic signal through the chest and lungs, which can accurately measure changes in lung fluid concentration.

Study summary

To explore whether a ReDS-guided strategy for AMI patients with cardiac insufficiency following coronary flow reperfusion is superior to routine care for improving outcomes.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Patients were required to be aged ≥ 18 years and to be hospitalized for a primary diagnosis of AMI, 2. AMI patients accompanied by cardiac insufficiency following coronary revascularization, which is characterized by the symptoms and signs of fluid overload, regardless of left ventricular ejection fraction (LVEF), and have an N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentration of ≥ 400 pg/L or a BNP concentration of ≥ 100 pg/L. Exclusion Criteria: 1. Patient's physical characteristics that prevented the use of the ReDS system (height of \<155 or \>190 cm; body mass index of \<22 or \>39 kg/m2) 2. Patients with chronic obstructive pulmonary disease or other lung diseases that might confound ReDS values 3. Patients with a left ventricular assist device or undergoing cardiac transplantation; 4. Patients with congenital heart malformations or intrathoracic mass that would affect right lung anatomy; 5. Patients with end-stage renal disease on hemodialysis; 6. Patients whose life expectancy less than 12 months due to noncardiac comorbidities 7. Patients who participate in another randomized studies.

Primary outcome measure(s)

  • Major adverse cardiac event (MACE) — 1 year
    The primary outcome is the MACE that is defined as a composite of all-cause death and HF readmission.

Trial sites (6)

FacilityCityRegionStatus
Huaihe Hospital of Henan University Kaifeng Henan
Kaifeng Central Hospital Kaifeng Henan
The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan
Shanghai Tenth People's Hospital Shanghai Shanghai Municipality
Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine Shanghai Shanghai Shanghai Municipality
Songjiang Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Shanghai Shanghai Municipality
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06671067 on ClinicalTrials.gov ↗ ← All trials in China